JNJ•JNJ•Johnson & Johnson's Shockwave Medical, acquired for $13.1 billion in June 2024, has launched its next-generation C2 Aero IVL catheter in May 2026 and intends to introduce one new catheter annually through 2030. The IVL sector, now 12–15% penetrated in US PCI procedures, is projected to reach $2 billion by 2034.
Johnson & Johnson acquired Shockwave Medical for $13.1 billion in June 2024 and has maintained its strategy of launching at least one new IVL catheter annually, most recently releasing the next-generation C2 Aero in May 2026. The company plans to continue this annual launch cadence through 2030 to sustain its first-mover advantage.
Shockwave’s IVL technology has achieved 12–15% penetration in US percutaneous coronary intervention procedures, with widespread adoption as physicians’ standard of care for treating severe calcified plaques. The sector is projected to exceed $2 billion by 2034, signaling substantial growth opportunities in both peripheral and coronary applications.
The company has generated over 600 peer-reviewed publications covering more than 25,000 treated patients, establishing a robust evidence base for safety and efficacy. Shockwave has also developed reimbursement pathways across multiple geographies, reinforcing its commercial position in key markets and enabling broader adoption.
Major medtech players like Boston Scientific, Stryker and Abbott are advancing IVL products, yet only Bolt Medical and Elixir Medical currently offer approved systems alongside Shockwave. Continuous device refinements—such as longer balloons and increased pulse counts—are aimed at differentiating Shockwave’s offering as global competitors enter the space.
